Redcare Pharmacy N.V. has increased its full-year 2026 revenue guidance for the second time in 2026, citing sustained momentum in prescription (Rx) revenue in Germany. The upgrade signals that the company's e-prescription strategy is delivering results ahead of internal expectations and reinforces its position as a leading online pharmacy in Europe.
The new guidance projects total revenue growth of 16% to 18%, up from the previously guided 15% to 17%. More significantly, Rx revenue in Germany is now expected to reach EUR 730 to 760 million, representing growth of 45% to 51%, compared to the prior range of EUR 680 to 720 million, which implied growth of 35% to 43%. Non-Rx growth guidance remains unchanged at 10% to 12%, and the adjusted EBITDA margin target is confirmed at 2.5% to 3.0%.
Preliminary figures show that Rx revenue in Germany grew by 51% year-on-year in September and 56% in the third quarter. September's performance was particularly notable given a high comparison base from the prior year, when the current Rx bonus was introduced. The company will release its full third-quarter 2026 figures on October 29, 2026.
“Our growth is backed by strong customer satisfaction: eRx NPS continues to rise, up 6 points year-on-year to 80 in August,” said Olaf Heinrich, CEO of Redcare Pharmacy. The rising Net Promoter Score suggests that customers are not only adopting the e-prescription service but also recommending it, which bodes well for customer retention and long-term revenue growth.
While Rx revenue remained strong throughout the quarter, non-Rx revenue in Germany rebounded well in August and September after a softer July. This rebound indicates that the overall German market remains resilient, and Redcare's diversified product offering can capture demand across categories.
The adjusted EBITDA margin remained flat quarter-on-quarter, benefiting from continued operating leverage. This is a positive signal: even as the company invests in growth, it is managing costs effectively and translating higher revenue into stable profitability. The ability to grow revenue at a double-digit pace while maintaining margins suggests that Redcare's scalable platform and logistics network are yielding efficiencies.
For investors, the guidance raise is a clear indication that Redcare's strategy of focusing on prescription drugs in Germany is paying off. The e-prescription market in Germany is still in its early stages, and Redcare's strong NPS and growing Rx revenue suggest it is well-positioned to capture a significant share. The company's European footprint, active in seven countries with over 14 million active customers, provides additional growth avenues.
The full details of the announcement are available on www.newmediawire.com. Redcare Pharmacy will publish its Interim Statement for the third quarter of 2026 and host its quarterly conference call on October 29, 2026. The company's shares are listed on the Frankfurt Stock Exchange (Prime Standard) and are part of the SDAX.
This second guidance raise in a single year highlights the accelerating adoption of digital healthcare solutions in Europe. As more patients and physicians embrace e-prescriptions, Redcare's early investments in technology and logistics are likely to continue driving growth, making it a company to watch in the evolving online pharmacy landscape.
